Acadia Pharma Secures FDA Fast Track Designation For Remlifanserin For Treatment Of Hallucinations And Delusions Associated With Alzheimer’s Disease Psychosis
-- Designation underscores the significant unmet need for new treatment options for Alzheimer’s disease psychosis, a serious condition with no FDA-approved therapies-- RADIANT Phase 2 enrollment completed, with topline
Acadia got special permission from the FDA to test a new medicine faster because there's no good treatment yet for a serious Alzheimer's problem. This shows the company is making progress, so watch if their test results are good or disappointing.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.